US Patent
US9580427 — Kinase inhibitors
Composition of Matter · Assigned to University of California San Diego UCSD · Expires 2033-03-01 · 7y remaining
Vulnerability score
17/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects compounds with a specific structure, such as Formula (XI), and methods of using them to inhibit kinases.
USPTO Abstract
Provided herein are compounds such as the compounds having the structure of Formula (XI) and methods of using the same, such as methods of inhibiting kinases.
Drugs covered by this patent
- Wayrilz (RILZABRUTINIB) · Genzyme Corp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.